Corporate GovernanceJun 12, 2026, 04:12 PM
Xilio Therapeutics Stockholders Approve Amended 2021 Stock Incentive Plan
AI Summary
Xilio Therapeutics, Inc. stockholders approved the Amended and Restated 2021 Stock Incentive Plan at the 2026 Annual Meeting, which includes adding shares underlying prefunded warrants to the annual evergreen increase calculation. Additionally, Daniel Curran, M.D., was re-appointed as a Class III director to achieve a more equal balance among the board's three classes. Stockholders also elected four Class II directors and ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Key Highlights
- Stockholders approved the Amended and Restated 2021 Stock Incentive Plan.
- The plan adds shares from prefunded warrants to the annual evergreen increase calculation.
- Daniel Curran, M.D., was re-appointed as a Class III director for board rebalancing.
- The Board now consists of three directors in each of Classes I, II, and III.
- Stockholders elected Akintunde Bello, Daniel Curran, Robert Ross, and Yuan Xu as Class II directors.
- Ernst & Young LLP was ratified as the independent auditor for fiscal year 2026.
- Votes For Amended 2021 Plan: 3,424,710; Against: 355,015.
- Votes For Auditor Ratification: 5,047,290; Against: 11,876.
Price Impact
More from XLO